STACEY BERG to CD56 Antigen
This is a "connection" page, showing publications STACEY BERG has written about CD56 Antigen.
Connection Strength
0.045
-
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 12 15; 126(24):5303-5310.
Score: 0.045